Tiberend Strategic Advisors, Inc. (Tiberend) is a full service corporate communications firm specializing in the healthcare and life sciences industry. Founded in 1989, Tiberend’s mission is to provide expert public and investor relations counsel to companies along the entire development lifecycle – from emerging, clinical-stage to publicly traded, revenue generating.
Tiberend creates individualized platforms for companies to communicate their value proposition to those audiences that have the greatest influence on their growth and success – investors, industry stakeholders, customers and the media.
Our goal is to be an integral component of our clients’ business, whether the aim is to complete a round of financing, secure a partner, advance a clinical trial or commercialize a newly launched product.
The Right Message to the Right Audience at the Right Time.
The Tiberend Team:
Gregory Q. Tiberend – President & CEO
Greg has 35+ years experience counseling senior management and has developed and executed strategic corporate communications programs for publicly traded and private companies. Greg co-founded Richard Lewis Communications, Inc. in 1989 and spent 10 years building the business and rejoined the firm in June 2005. In May 2008, Greg became president & CEO. In 2009, the firm’s name was changed to Tiberend Strategic Advisors, Inc.
Prior to re-joining the firm, Greg spent three years leading the healthcare practice as Executive Vice President at The Ruth Group where he built significant revenue for the life sciences group and counseled senior management on investor communications programs.
From 1999 to 2002, Greg was a Vice President at Morgen-Walke Associates, Inc. (now Financial Dynamics) where he led multiple practice areas – healthcare and business services. Early in his career, Greg was Communications Manager for American Cyanamid’s International Agricultural Division where he worked on a global basis with country managers in developing and building communications programs for animal health biologics and crop protection chemicals.
Having developed strong relationships during his career with investment bankers, venture capitalist and journalists, Greg has counseled more than 200 companies in the areas of biotechnology, specialty pharmaceutical, generic pharmaceutical, medical device, medical technology, diagnostics, healthcare services and financial services. He has a strong understanding of the stories investors and journalists are seeking and works with clients to develop key messages to best that will resonate with multiple audiences including investors and potential partners.
Greg is a 1984 graduate of the University of Illinois at Urbana-Champaign.
Jason Rando – Executive Vice President & Chief Operating Officer
Jason is responsible for guiding the firm’s strategic direction as well as the day-to-day management of its clients’ investor communications and public relations programs. From media visibility to product marketing to patient and physician education, Jason works with the Tiberend team to design individualized communications programs that enable the firm’s clients to direct their message to the audiences most integral to the growth of their business.
With 25+ years industry experience, Jason has specialized in establishing and managing high-level communications programs for public and private companies in a number of industries, including healthcare (biotech, pharmaceutical, medical technology), financial services and technology. During Jason’s career, his close ties with the top-tier national media have generated significant client exposure, including feature coverage in The Wall Street Journal, The New York Times, Bloomberg BusinessWeek, Dow Jones, Reuters, Forbes, Fortune, Investor’s Business Daily, and 300+ executive and financial analyst interviews on CNBC.
Prior to joining Tiberend Strategic Advisors, Jason spent nine years at The Ruth Group with increasing levels of responsibility, most recently as Senior Vice President, Public Relations and Healthcare Marketing.
Jason is a 1994 graduate of Tufts University with a degree in psychology.
Jonathan Nugent – EVP, Investor Relations
Jon has more than 25 years of experience developing innovative investor relations strategies for leading companies in North America, Europe, and Asia. He has served as the in-house Vice President of Investor Relations and Corporate Communications for private and public companies in a multitude of therapeutic areas including oncology, infectious disease, and ophthalmology.
In addition to providing senior-level in-house investor relations and communications counsel, Jon has spent much of his career on the agency side with healthcare focused investor and media relations firms. In that capacity, Jon has worked with over 200 of the industry’s most dynamic and
innovative biopharmaceutical companies through all phases of corporate development including commercialization. He has extensive experience working with a range of healthcare companies, from preclinical platform companies to established commercial companies, and across a number of
therapeutic areas including rare diseases, central nervous system disorders, gastroenterology and hepatology, gene regulation, and oncology, along with companies focused on diagnostics and specialty pharmaceuticals. Over the years, Jon has worked with clients including Gilead Sciences, Pfizer, Bayer, Human Genome Sciences, Alkermes, Cephalon, COR Therapeutics, OSI
Pharmaceuticals, SUGEN, AryX Therapeutics, and BioCryst Pharmaceuticals.
Additionally, Jon has helped numerous private companies navigate the initial public offering process through both favorable and challenging market conditions, establishing appropriate infrastructure and guiding them through complex strategic issues. Leveraging analytics, Jon helps his clients develop relationships with key contacts in the investment community, optimizing their visibility through conferences, medical meetings, KOL events, and one-on-one meetings. He has successfully advised companies through corporate restructurings, operational turnarounds, corporate alliances, mergers and acquisitions, FDA advisory committee meetings, and clinical challenges.
Jon holds a BA from Lake Forest College and an MBA from the University of Alabama at Birmingham.
Daniel Kontoh-Boateng – VP, Investor Relations
Daniel Kontoh-Boateng has spent more than five years providing investor relations counsel to numerous public and private life science companies. During his most recent tenure at The Ruth Group, he developed and implemented strategic investor communications programs that aligned clients with the expectations of investors and stakeholders.
Over the course of his IR career, Daniel has garnered significant expertise with capital markets advisory and investor education and outreach, which has proved valuable to clients. His work includes guidance on IR best practices, introductions to investors, analysts and investment bankers, funding strategies, financier introductions/evaluation, follow-on transaction advice, M&A
communications, and pre-and-post IPO support.
Daniel holds a BA in Communications with a minor in legal studies from Seton Hall University.